SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-17 EDT			5-day change	1st Jan Change
2.92 ^USD	-5.35%		-8.75%	-57.53%

07-01	SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell 3000E Index	CI
07-01	SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Index	CI

SAB BIOTHERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)

January 10, 2022 at 06:05 am

Item 7.01 Regulation FD Disclosure.

On January 5, 2022, SAB Biotherapeutics, Inc. (the "Company") previously announced that Eddie J. Sullivan, PhD., co-founder, president, and CEO, would present at the H.C. Wainwright BioConnect Virtual Conference held during January 10-13, 2022. Following such announcement, the Company determined that it will not participate in the H.C. Wainwright BioConnect Virtual Conference. As a result, there will be no on-demand webcast of the presentation on the Company's website.

Latest news about SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell 3000E Index	06-30	CI
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Index	06-30	CI
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Value Index	06-30	CI
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell 3000E Value Index	06-30	CI
SAB Biotherapeutics, Inc. has Changed its Name to SAB BIO	06-20	CI
Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target	06-07	MT
SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer	05-30	CI
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics	05-21	CI
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors	05-06	CI
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	04-16	CI
HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating	04-02	MT
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline	03-25	MT
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	03-25	CI
SAB Biotherapeutics Executive Chairman Samuel Reich Adds CEO Role	02-02	MT
SAB Biotherapeutics, Inc. Announces CEO Changes	02-02	CI
SAB Biotherapeutics Regains Nasdaq Compliance	01-24	MT
SAB Biotherapeutics to Effect 1-for-10 Reverse Stock Split; Shares Fall After-Hours	01-02	MT
SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142	11-29	CI
SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors	11-20	CI
HC Wainwright Trims SAB Biotherapeutics' Price Target to $1 From $2, Keeps Buy Rating	11-14	MT
SAB Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
SAB Biotherapeutics, Inc. Appoints Michael G. King Jr. as Chief Financial Officer	23-10-24	CI
North American Morning Briefing : Investors Await -2-	23-10-06	DJ

Chart SAB Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.92 USD

Average target price

13 USD

Spread / Average Target

+345.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAB BIOTHERAPEUTICS, INC.	-57.53%	26.95M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.71%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-15.43%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs